Studies of scintillator response to 60 MeV protons in a proton beam imaging system

A Proton Beam Imaging System (ProBImS) is under development at the Institute of Nuclear Physics, Polish Academy of Sciences (IFJ PAN). The ProBImS will be used to optimize beam delivery at IFJ PAN proton therapy facilities, delivering two-dimensional distributions of beam profiles. The system consists of a scintillator, optical tract and a sensitive CCD camera which digitally records the light emitted from the proton-irradiated scintillator. The optical system, imaging data transfer and control software have already been developed. Here, we report preliminary results of an evaluation of the DuPont Hi-speed thick back screen EJ 000128 scintillator to determine its applicability in our imaging system. In order to optimize the light conversion with respect to the dose locally deposited by the proton beam in the scintillation detector, we have studied the response of the DuPont scintillator in terms of linearity of dose response, uniformity of light emission and decay rate of background light after deposition of a high dose in the scintillator. We found a linear dependence of scintillator light output vs. beam intensity by showing the intensity of the recorded images to be proportional to the dose deposited in the scintillator volume

Studies of scintillator response to 60 MeV protons in a proton beam imaging system

A Proton Beam Imaging System (ProBImS) is under development at the Institute of Nuclear Physics, Polish Academy of Sciences (IFJ PAN). The ProBImS will be used to optimize beam delivery at IFJ PAN proton therapy facilities, delivering two-dimensional distributions of beam profiles. The system consists of a scintillator, optical tract and a sensitive CCD camera which digitally records the light emitted from the proton-irradiated scintillator. The optical system, imaging data transfer and control software have already been developed. Here, we report preliminary results of an evaluation of the DuPont Hi-speed thick back screen EJ 000128 scintillator to determine its applicability in our imaging system. In order to optimize the light conversion with respect to the dose locally deposited by the proton beam in the scintillation detector, we have studied the response of the DuPont scintillator in terms of linearity of dose response, uniformity of light emission and decay rate of background light after deposition of a high dose in the scintillator. We found a linear dependence of scintillator light output vs. beam intensity by showing the intensity of the recorded images to be proportional to the dose deposited in the scintillator volume

Application of alanine dosimetry in dose assessment for ocular melanoma patients undergoing proton radiotherapy – preliminary results

Basing on alanine solid state/electron paramagnetic resonance (EPR) dosimetry, a supplementary method of cumulatively recording the therapeutic dose received by ocular cancer patients undergoing fractionated proton radiotherapy is proposed. By applying alanine dosimetry during the delivery of consecutive fractions, the dose received within each fraction can be read out by EPR spectrometry and a final permanent cumulative record of the total dose delivered obtained. The dose response of the alanine detector was found to be practically independent on its position within the extended proton Bragg peak region. Dose measurements based on entrance dose recorded in proton beams individually formed for each patient are presented. The described method will be applied as a complementary Quality Assurance procedure for patients undergoing proton radiotherapy at the Institute of Nuclear Physics, Polish Academy of Sciences, Krakow, Poland (IFJ PAN)

A Simple Approach for Experimental Characterization and Validation of Proton Pencil Beam Profiles

International audienceA precise characterization of therapeutic proton pencil beams is essential for commissioning of any treatment planning system (TPS). The dose profile characterization includes measurement of the beam lateral dose profile in the beam core and far from the beam core, in the so called low-dose envelope, and requires a sophisticated detection system with a few orders of magnitude dynamic range. We propose to use a single-quantum sensitive Minipix Timepix detector, along with an in-house designed holder to perform measurements of the pencil beam dose profile in air and in water. We validated the manufacturer calibration of the Minipix Timepix detector in proton beams of various energies and compared the deposited energy spectra to Monte Carlo (MC) simulations. The precision of the lateral dose profile measurements has been systematically validated against Krakow proton facility commissioning data and dose profile simulations performed with MC codes Gate/Geant4 and Fred. We obtained an excellent agreement between Minipix Timepix measurements and simulations demonstrating the feasibility of the system for a simple characterization and validation of proton pencil beams. The proposed approach can be implemented at any proton therapy facility to acquire experimental data needed to commission and validate analytical and MC based TPS

Quantification of biological range uncertainties in patients treated at the Krakow proton therapy centre

BACKGROUND: Variable relative biological effectiveness (vRBE) in proton therapy might significantly modify the prediction of RBE-weighted dose delivered to a patient during proton therapy. In this study we will present a method to quantify the biological range extension of the proton beam, which results from the application of vRBE approach in RBE-weighted dose calculation. METHODS AND MATERIALS: The treatment plans of 95 patients (brain and skull base patients) were used for RBE-weighted dose calculation with constant and the McNamara RBE model. For this purpose the Monte Carlo tool FRED was used. The RBE-weighted dose distributions were analysed using indices from dose-volume histograms. We used the volumes receiving at least 95% of the prescribed dose (V95) to estimate the biological range extension resulting from vRBE approach. RESULTS: The vRBE model shows higher median value of relative deposited dose and D95 in the planning target volume by around 1% for brain patients and 4% for skull base patients. The maximum doses in organs at risk calculated with vRBE was up to 14 Gy above dose limit. The mean biological range extension was greater than 0.4 cm. DISCUSSION: Our method of estimation of biological range extension is insensitive for dose inhomogeneities and can be easily used for different proton plans with intensity-modulated proton therapy (IMPT) optimization. Using volumes instead of dose profiles, which is the common method, is more universal. However it was tested only for IMPT plans on fields arranged around the tumor area. CONCLUSIONS: Adopting a vRBE model results in an increase in dose and an extension of the beam range, which is especially disadvantageous in cancers close to organs at risk. Our results support the need to re-optimization of proton treatment plans when considering vRBE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-022-02022-5

Quantification of biological range uncertainties in patients treated at the Krakow proton therapy centre

International audienceBackground: Variable relative biological effectiveness (vRBE) in proton therapy might significantly modify the prediction of RBE-weighted dose delivered to a patient during proton therapy. In this study we will present a method to quantify the biological range extension of the proton beam, which results from the application of vRBE approach in RBE-weighted dose calculation.Methods and materials: The treatment plans of 95 patients (brain and skull base patients) were used for RBE-weighted dose calculation with constant and the McNamara RBE model. For this purpose the Monte Carlo tool FRED was used. The RBE-weighted dose distributions were analysed using indices from dose-volume histograms. We used the volumes receiving at least 95% of the prescribed dose (V95) to estimate the biological range extension resulting from vRBE approach.Results: The vRBE model shows higher median value of relative deposited dose and D95 in the planning target volume by around 1% for brain patients and 4% for skull base patients. The maximum doses in organs at risk calculated with vRBE was up to 14 Gy above dose limit. The mean biological range extension was greater than 0.4 cm.Discussion: Our method of estimation of biological range extension is insensitive for dose inhomogeneities and can be easily used for different proton plans with intensity-modulated proton therapy (IMPT) optimization. Using volumes instead of dose profiles, which is the common method, is more universal. However it was tested only for IMPT plans on fields arranged around the tumor area.Conclusions: Adopting a vRBE model results in an increase in dose and an extension of the beam range, which is especially disadvantageous in cancers close to organs at risk. Our results support the need to re-optimization of proton treatment plans when considering vRBE

Study of relationship between dose, LET and the risk of brain necrosis after proton therapy for skull base tumors

International audiencePurposeWe investigated the relationship between RBE-weighted dose (DRBE) calculated with constant (cRBE) and variable RBE (vRBE), dose-averaged linear energy transfer (LETd) and the risk of radiographic changes in skull base patients treated with protons.MethodsClinical treatment plans of 45 patients were recalculated with Monte Carlo tool FRED. Radiographic changes (i.e. edema and/or necrosis) were identified by MRI. Dosimetric parameters for cRBE and vRBE were computed. Biological margin extension and voxel-based analysis were employed looking for association of DRBE(vRBE) and LETd with brain edema and/or necrosis.ResultsWhen using vRBE, Dmax in the brain was above the highest dose limits for 38% of patients, while such limit was never exceeded assuming cRBE. Similar values of Dmax were observed in necrotic regions, brain and temporal lobes. Most of the brain necrosis was in proximity to the PTV. The voxel-based analysis did not show evidence of an association with high LETd values.ConclusionsWhen looking at standard dosimetric parameters, the higher dose associated with vRBE seems to be responsible for an enhanced risk of radiographic changes. However, as revealed by a voxel-based analysis, the large inter-patient variability hinders the identification of a clear effect for high LETd